[
    {
        "ID": "001",
        "IHC Code": "IHC-007-001",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "NA",
        "Family/class(2022 WHO)": "Tumour-like lesions with B-cell predominance",
        "Subtype/entity(Interlymph 2024)": "Reactive B-cell-rich lymphoid proliferations that can mimic lymphoma",
        "Category": "NA",
        "L1": "LN",
        "L2": "NHL",
        "L3": "NA",
        "L4": "NA",
        "L5": "NA",
        "L6": "NA"
    },
    {
        "ID": "002",
        "IHC Code": "IHC-007-002",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "NA",
        "Family/class(2022 WHO)": "Tumour-like lesions with B-cell predominance",
        "Subtype/entity(Interlymph 2024)": "IgG4-related disease",
        "Category": "NA",
        "L1": "LN",
        "L2": "NHL",
        "L3": "NA",
        "L4": "NA",
        "L5": "NA",
        "L6": "NA"
    },
    {
        "ID": "003",
        "IHC Code": "IHC-007-003",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "NA",
        "Family/class(2022 WHO)": "Tumour-like lesions with B-cell predominance",
        "Subtype/entity(Interlymph 2024)": "Unicentric Castleman disease",
        "Category": "NA",
        "L1": "LN",
        "L2": "NHL",
        "L3": "NA",
        "L4": "NA",
        "L5": "NA",
        "L6": "NA"
    },
    {
        "ID": "004",
        "IHC Code": "IHC-007-004",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "NA",
        "Family/class(2022 WHO)": "Tumour-like lesions with B-cell predominance",
        "Subtype/entity(Interlymph 2024)": "Idiopathic multicentric Castleman disease",
        "Category": "NA",
        "L1": "LN",
        "L2": "NHL",
        "L3": "NA",
        "L4": "NA",
        "L5": "NA",
        "L6": "NA"
    },
    {
        "ID": "005",
        "IHC Code": "IHC-007-005",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "NA",
        "Family/class(2022 WHO)": "Tumour-like lesions with B-cell predominance",
        "Subtype/entity(Interlymph 2024)": "KSHV/HHV8-associated multicentric Castleman disease",
        "Category": "Multicentric Castleman disease",
        "L1": "LN",
        "L2": "NHL",
        "L3": "NA",
        "L4": "NA",
        "L5": "NA",
        "L6": "NA"
    },
    {
        "ID": "006",
        "IHC Code": "IHC-000-006",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Precursor B-cell neoplasms",
        "Family/class(2022 WHO)": "B-cell lymphoblastic leukaemias/lymphomas",
        "Subtype/entity(Interlymph 2024)": "Precursor acute lymphoblastic leukemia/lymphoma, B-cell, NOS (B-ALL/LBL, NOS)",
        "Category": "Precursor acute lymphoblastic leukemia/lymphoma, B-cell, NOS (B-ALL/LBL, NOS)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Precursor B-cell neoplasm",
        "L4": "B-cell lymphoblastic leukemias/lymphomas",
        "L5": "B-ALL / LBL,NOS",
        "L6": "B-ALL or LBL,NOS"
    },
    {
        "ID": "007",
        "IHC Code": "IHC-000-007",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Precursor B-cell neoplasms",
        "Family/class(2022 WHO)": "B-cell lymphoblastic leukaemias/lymphomas",
        "Subtype/entity(Interlymph 2024)": "Precursor B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities (12 subtypes) (B-ALL/LBL-RGA) (b)",
        "Category": "Precursor B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities (7 subtypes) (B-ALL/LBL-RGA)b",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Precursor B-cell neoplasm",
        "L4": "B-cell lymphoblastic leukemias/lymphomas",
        "L5": "B-ALL / LBL-RGA (b)",
        "L6": "B-ALL with other defined genetic abnormalities (ex: B-ALL with DUX4, MEF2D,ZNF384,NTM1 rearrangements, IG:MYC fusion and PAX5alt or PAX5 p.P80R abnormalities."
    },
    {
        "ID": "008",
        "IHC Code": "IHC-001-008",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Pre-neoplastic and neoplastic small lymphocytic proliferations",
        "Subtype/entity(Interlymph 2024)": "Monoclonal B-cell lymphocytosis, CLL and non-CLL phenotype (MBL)",
        "Category": "Monoclonal B-cell lymphocytosis, CLL and non-CLL phenotype (MBL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "Pre-neoplastic and neoplastic small lymphocytic proliferations",
        "L5": "Monoclonal B-cell lymphocytosis, CLL and non-CLL phenotype (MBL)",
        "L6": "MBL (Low-count MBL or clinal B-cell expansion, CLL/SLL-type MBL, non-CLL/SLL-type MBL)"
    },
    {
        "ID": "009",
        "IHC Code": "IHC-001-009",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Pre-neoplastic and neoplastic small lymphocytic proliferations",
        "Subtype/entity(Interlymph 2024)": "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)",
        "Category": "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "Pre-neoplastic and neoplastic small lymphocytic proliferations",
        "L5": "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)",
        "L6": "CLL or SLL"
    },
    {
        "ID": "010",
        "IHC Code": "IHC-001-010",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Pre-neoplastic and neoplastic small lymphocytic proliferations",
        "Subtype/entity(Interlymph 2024)": "Entity deleted (B-PLL is no longer recognized as an entity)",
        "Category": "Prolymphocytic leukemia , B-cell (B-PLL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "CLL/SLL/B-PLL/MCL",
        "L5": "B-PLL",
        "L6": ""
    },
    {
        "ID": "011",
        "IHC Code": "IHC-001-011",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Splenic B-cell lymphomas and leukemias (term replaces hary cell leukemia variant and CD5-negative B-cell prolymphocytic leukemia)",
        "Subtype/entity(Interlymph 2024)": "Hairy cell leukemia (HCL)",
        "Category": "Hairy cell leukemia (HCL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "Splenic B-cell lymphomas and leukemias",
        "L5": "HCL",
        "L6": ""
    },
    {
        "ID": "012",
        "IHC Code": "IHC-001-012",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Splenic B-cell lymphomas and leukemias (term replaces hary cell leukemia variant and CD5-negative B-cell prolymphocytic leukemia)",
        "Subtype/entity(Interlymph 2024)": "Splenic marginal zone lymphoma (SMZL)",
        "Category": "Splenic marginal zone lymphoma (SMZL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "Splenic B-cell lymphomas and leukemias",
        "L5": "SMZL",
        "L6": ""
    },
    {
        "ID": "013",
        "IHC Code": "IHC-001-013",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Splenic B-cell lymphomas and leukemias (term replaces hary cell leukemia variant and CD5-negative B-cell prolymphocytic leukemia)",
        "Subtype/entity(Interlymph 2024)": "Splenic diffuse red pulp small B-cell lymphoma (splenic red pulp BCL) (SDRPL)",
        "Category": "Splenic diffuse red pulp small B-cell lymphoma (splenic red pulp BCL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "Splenic B-cell lymphomas and leukemias",
        "L5": "SDRPL",
        "L6": ""
    },
    {
        "ID": "014",
        "IHC Code": "IHC-001-014",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Splenic B-cell lymphomas and leukemias (term replaces hary cell leukemia variant and CD5-negative B-cell prolymphocytic leukemia)",
        "Subtype/entity(Interlymph 2024)": "Splenic B-cell lymphoma/leukemia with prominent nucleoli (encompassing hairy cell leukemia variant and some cases of B-cell prolymphocytic leukemia) (SBLPN)",
        "Category": "Hairy cell leukemia-variant (HCL-V)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "Splenic B-cell lymphomas and leukemias",
        "L5": "SBLPN / B-PLL",
        "L6": "SBLPN or B-PLL"
    },
    {
        "ID": "015",
        "IHC Code": "IHC-001-015",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Splenic B-cell lymphomas and leukemias (term replaces hary cell leukemia variant and CD5-negative B-cell prolymphocytic leukemia)",
        "Subtype/entity(Interlymph 2024)": "Splenic B-cell lymphoma/leukemia, unclassifiable (splenic BCL,U)",
        "Category": "Splenic B-cell lymphoma/leukemia, unclassifiable (splenic BCL,U)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "Splenic B-cell lymphomas and leukemias",
        "L5": "Splenic B-cell lymphoma/leukemia, unclassifiable (splenic BCL,U)",
        "L6": ""
    },
    {
        "ID": "016",
        "IHC Code": "IHC-001-016",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Lymphoplasmacytic lymphoma (LPL) (IgM matters)",
        "Subtype/entity(Interlymph 2024)": "Lymphoplasmacytic lymphoma (c), including cases with Waldenstrom macroglubinaemia an gamma heavy chain disease (LPL) (d)",
        "Category": "Lymphoplasmacytic lymphoma (c), including cases with Waldenstrom macroglubinaemia an gamma heavy chain disease (LPL) (d)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "LPL",
        "L5": "LPL (c )",
        "L6": "IgM-LPL/WM type, Non-WM type LPL"
    },
    {
        "ID": "017",
        "IHC Code": "IHC-001-017",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Marginal zone lymphoma other than splenic",
        "Subtype/entity(Interlymph 2024)": "Extranodal marginal zone lymphoma and mucosa associated lymphoid tissue (MALT lymphoma) (MALT) (e)",
        "Category": "Extranodal marginal zone lymphoma and mucosa=-associated lymphoid tissue (MALT lymphoma) (MALT) â‚¬",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "MZL",
        "L5": "EMZL",
        "L6": "EMZL-type, MALT (e)"
    },
    {
        "ID": "018",
        "IHC Code": "IHC-001-018",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Marginal zone lymphoma other than splenic",
        "Subtype/entity(Interlymph 2024)": "Primary cutaneous marginal zone lymphoma (originally included under \"extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue\") (e)",
        "Category": "Not previously included (e)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "MZL",
        "L5": "PCMZL",
        "L6": ""
    },
    {
        "ID": "019",
        "IHC Code": "IHC-001-019",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Marginal zone lymphoma other than splenic",
        "Subtype/entity(Interlymph 2024)": "Nodal marginal zone lymphoma (NMZL) (e)",
        "Category": "Nodal marginal zone lymphoma (NMZL) (e)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "MZL",
        "L5": "NMZL",
        "L6": ""
    },
    {
        "ID": "020",
        "IHC Code": "IHC-001-020",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Marginal zone lymphoma other than splenic",
        "Subtype/entity(Interlymph 2024)": "Pediatric nodal marginal zone lymphoma (pNMZL) (e,f,g)",
        "Category": "Pediatric nodal marginal zone lymphoma (NMZL-PED) (e,f,g)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "MZL",
        "L5": "pNMZL",
        "L6": ""
    },
    {
        "ID": "021",
        "IHC Code": "IHC-001-021",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Follicular lymphoma (FL)",
        "Subtype/entity(Interlymph 2024)": "Classic Follicular lymphoma (FL) (grades 1-3a optional but excludes FL 3b which is now follicular large B cell lymphoma",
        "Category": "Follicular lymphoma (FL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "FL",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "022",
        "IHC Code": "IHC-001-022",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Follicular lymphoma (FL)",
        "Subtype/entity(Interlymph 2024)": "Follicular large B-cell lymphoma",
        "Category": "",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "FL",
        "L5": "classic FL (cFL)",
        "L6": "follicular large B-cell lymphoma (FLBL), FL with uncommon features (uFL)"
    },
    {
        "ID": "023",
        "IHC Code": "IHC-001-023",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Follicular lymphoma (FL)",
        "Subtype/entity(Interlymph 2024)": "Pediatric-type  follicular lymphoma (FL-PED) (f)",
        "Category": "Pediatric follicular lymphoma (FL-PED) (f)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "FL",
        "L5": "FL-PED",
        "L6": ""
    },
    {
        "ID": "024",
        "IHC Code": "IHC-001-024",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Follicular lymphoma (FL)",
        "Subtype/entity(Interlymph 2024)": "Duodenal-type follicular lymphoma (quite different from PED)",
        "Category": "",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "FL",
        "L5": "pediatric-type and duodenal FL",
        "L6": "pediatric-type FL, duodenal FL"
    },
    {
        "ID": "025",
        "IHC Code": "IHC-001-025",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Follicular lymphoma (FL)",
        "Subtype/entity(Interlymph 2024)": "Primary cutaneous follicular centre lymphoma (PCFCL)",
        "Category": "Primary cutaneous follicular centre lymphoma (PCFCL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "FL",
        "L5": "PCFCL",
        "L6": ""
    },
    {
        "ID": "026",
        "IHC Code": "IHC-001-026",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Follicular lymphoma (FL)",
        "Subtype/entity(Interlymph 2024)": "In situ follicular B-cell neoplasm / \"In situ\" follicular lymphoma (ISFN)",
        "Category": "In situ follicular neoplasia / \"In situ\" follicular lymphoma (FL-in situ)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "FL",
        "L5": "ISFN",
        "L6": ""
    },
    {
        "ID": "027",
        "IHC Code": "IHC-001-027",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Mantle cell lymphoma",
        "Subtype/entity(Interlymph 2024)": "in situ\" mantle cell neoplasm",
        "Category": "LN",
        "L1": "NHL",
        "L2": "Mature B-cell neoplasms",
        "L3": "LP/LPL-IDD",
        "L4": "Hyperplasias arising in immune deficiency/dysregulation",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "055",
        "IHC Code": "IHC-001-055",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Lymphoid proliferations and lymphomas associated with Immune deficiency and dysregulation (LP/LPL-IDD)",
        "Subtype/entity(Interlymph 2024)": "Polymorphic lymphoproliferative disorders arising in immune deficiency/dysregulation",
        "Category": "Not previously included, encompassing polymorphic posttransplant\nlymphoproliferative disorders, other iatrogenic immunodeficiency-associated\nlymphoproliferative disorders, among others",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "LP/LPL-IDD",
        "L5": "Polymorphic lymphoproliferative disorders arising in immune deficiency/dysregulation",
        "L6": ""
    },
    {
        "ID": "056",
        "IHC Code": "IHC-001-056",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Lymphoid proliferations and lymphomas associated with Immune deficiency and dysregulation (LP/LPL-IDD)",
        "Subtype/entity(Interlymph 2024)": "EBV-positive mucocutaneous ulcer",
        "Category": "EBV-positive mucocutaneuous ulcer",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "LP/LPL-IDD",
        "L5": "EBV-positive mucocutaneuous ulcer",
        "L6": ""
    },
    {
        "ID": "057",
        "IHC Code": "IHC-001-057",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Lymphoid proliferations and lymphomas associated with Immune deficiency and dysregulation (LP/LPL-IDD)",
        "Subtype/entity(Interlymph 2024)": "Lymphomas arising in immune deficiency/dysregulation (classify as for immunocompetent patient)",
        "Category": "Not previously included, encompassing monomorphic posttransplant\nlymphoproliferative disorders, classic Hodgkin lymphoma posttransplant\nlymphoproliferative disorders, lymphomas associated with HIV infection,\namong others",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "LP/LPL-IDD",
        "L5": "Lymphomas arising in immune deficiency/dysregulation",
        "L6": ""
    },
    {
        "ID": "058",
        "IHC Code": "IHC-001-058",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Lymphoid proliferations and lymphomas associated with Immune deficiency and dysregulation (LP/LPL-IDD)",
        "Subtype/entity(Interlymph 2024)": "Inborn error of immunity-associated lymphoid proliferations and lymphomas (non-neoplastic or lymphoma/leukaemia)",
        "Category": "Lymphoproliferative diseases associated with primary immune disorders",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature B-cell neoplasms",
        "L4": "LP/LPL-IDD-IEI",
        "L5": "Inborn error of immunity-associated lymphoid proliferations and lymphomas",
        "L6": ""
    },
    {
        "ID": "059",
        "IHC Code": "IHC-011-059",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Hodgkin lymphoma (HL)",
        "Subtype/entity(Interlymph 2024)": "Classical Hodgkin lymphoma, lymphocyte-rich (LRCHL)",
        "Category": "Classical Hodgkin lymphoma, lymphocyte-rich (LRCHL)",
        "L1": "LN",
        "L2": "HL",
        "L3": "Mature B-cell neoplasms",
        "L4": "HL",
        "L5": "CHL",
        "L6": "LRCHL"
    },
    {
        "ID": "060",
        "IHC Code": "IHC-011-060",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Hodgkin lymphoma (HL)",
        "Subtype/entity(Interlymph 2024)": "Classical Hodgkin lymphoma, mixed cellularity (MCCHL)",
        "Category": "Classical Hodgkin lymphoma, mixed cellularity (MCCHL)",
        "L1": "LN",
        "L2": "HL",
        "L3": "Mature B-cell neoplasms",
        "L4": "HL",
        "L5": "CHL",
        "L6": "MCCHL"
    },
    {
        "ID": "061",
        "IHC Code": "IHC-011-061",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Hodgkin lymphoma (HL)",
        "Subtype/entity(Interlymph 2024)": "Classical Hodgkin lymphoma, lymphocyte-depleted (LDCHL)",
        "Category": "Classical Hodgkin lymphoma, lymphocyte-depleted (LDCHL)",
        "L1": "LN",
        "L2": "HL",
        "L3": "Mature B-cell neoplasms",
        "L4": "HL",
        "L5": "CHL",
        "L6": "LDCHL"
    },
    {
        "ID": "062",
        "IHC Code": "IHC-011-062",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Hodgkin lymphoma (HL)",
        "Subtype/entity(Interlymph 2024)": "Classical Hodgkin lymphoma, nodular sclerosis (NSCHL)",
        "Category": "Classical Hodgkin lymphoma, nodular sclerosis (NSCHL)",
        "L1": "LN",
        "L2": "HL",
        "L3": "Mature B-cell neoplasms",
        "L4": "HL",
        "L5": "CHL",
        "L6": "NSCHL"
    },
    {
        "ID": "063",
        "IHC Code": "IHC-011-063",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Hodgkin lymphoma (HL)",
        "Subtype/entity(Interlymph 2024)": "Classical Hodgkin lymphoma, not otherwise specified (CHL, NOS)",
        "Category": "Classical Hodgkin lymphoma, not otherwise specified (CHL, NOS)",
        "L1": "LN",
        "L2": "HL",
        "L3": "Mature B-cell neoplasms",
        "L4": "HL",
        "L5": "CHL",
        "L6": "CHL, NOS"
    },
    {
        "ID": "064",
        "IHC Code": "IHC-011-064",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Mature B-cell neoplasms",
        "Family/class(2022 WHO)": "Hodgkin lymphoma (HL)",
        "Subtype/entity(Interlymph 2024)": "Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)",
        "Category": "Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)",
        "L1": "LN",
        "L2": "HL",
        "L3": "Mature B-cell neoplasms",
        "L4": "HL",
        "L5": "NLPHL",
        "L6": ""
    },
    {
        "ID": "065",
        "IHC Code": "IHC-006-065",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Monoclonal gammopathies",
        "Subtype/entity(Interlymph 2024)": "Cold agglutinin disease (CAD)",
        "Category": "Not previously included",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Monoclonal gammopathies",
        "L5": "CAD",
        "L6": ""
    },
    {
        "ID": "066",
        "IHC Code": "IHC-006-066",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Monoclonal gammopathies",
        "Subtype/entity(Interlymph 2024)": "Monoclonal gammopathy of undetermined significance (MGUS) ",
        "Category": "Monoclonal gammopathy of undetermined significance (MGUS)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Monoclonal gammopathies",
        "L5": "MGUS",
        "L6": ""
    },
    {
        "ID": "067",
        "IHC Code": "IHC-006-067",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Monoclonal gammopathies",
        "Subtype/entity(Interlymph 2024)": "IgM Monoclonal gammopathy of undetermined significance (MGUS) ",
        "Category": "IgM Monoclonal gammopathy of undetermined significance (MGUS) ",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Monoclonal gammopathies",
        "L5": "IgM-MGUS",
        "L6": ""
    },
    {
        "ID": "068",
        "IHC Code": "IHC-006-068",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Monoclonal gammopathies",
        "Subtype/entity(Interlymph 2024)": "Non-IgM Monoclonal gammopathy of undetermined significance (MGUS) ",
        "Category": "Non-IgM Monoclonal gammopathy of undetermined significance (MGUS) ",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Monoclonal gammopathies",
        "L5": "non-IgM-MGUS",
        "L6": ""
    },
    {
        "ID": "069",
        "IHC Code": "IHC-006-069",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Monoclonal gammopathies",
        "Subtype/entity(Interlymph 2024)": "Monoclonal gammopathy of renal significance (MGRS)",
        "Category": "Not previously included",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Monoclonal gammopathies",
        "L5": "MGRS",
        "L6": ""
    },
    {
        "ID": "070",
        "IHC Code": "IHC-006-070",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Diseases with monoclonal Immunoglobulin deposition",
        "Subtype/entity(Interlymph 2024)": "Immunoglobulin-related (AL) amyloidosis",
        "Category": "Primary amyloidosis",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Diseases with monoclonal Immunoglobulin deposition",
        "L5": "AL",
        "L6": ""
    },
    {
        "ID": "071",
        "IHC Code": "IHC-006-071",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Diseases with monoclonal Immunoglobulin deposition",
        "Subtype/entity(Interlymph 2024)": "Monoclonal immunoglobulin deposition disease",
        "Category": "Light chain and heavy chain deposition disease",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Diseases with monoclonal Immunoglobulin deposition",
        "L5": "Monoclonal immunoglobulin deposition disease",
        "L6": ""
    },
    {
        "ID": "072",
        "IHC Code": "IHC-006-072",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Heavy chain diseases",
        "Subtype/entity(Interlymph 2024)": "Mu heavy chain disease",
        "Category": "Mu heavy chain disease",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Heavy chain diseases",
        "L5": "Mu heavy chain",
        "L6": ""
    },
    {
        "ID": "073",
        "IHC Code": "IHC-006-073",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Heavy chain diseases",
        "Subtype/entity(Interlymph 2024)": "Gamma heavy chain disease",
        "Category": "Gamma heavy chain disease",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Heavy chain diseases",
        "L5": "Gamma heavy chain disease",
        "L6": ""
    },
    {
        "ID": "074",
        "IHC Code": "IHC-006-074",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Heavy chain diseases",
        "Subtype/entity(Interlymph 2024)": "Alpha heavy chain disease",
        "Category": "Alpha heavy chain disease",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "Heavy chain diseases",
        "L5": "Alpha heavy chain disease",
        "L6": ""
    },
    {
        "ID": "075",
        "IHC Code": "IHC-006-075",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Plasma cell neoplasms (PCN)",
        "Subtype/entity(Interlymph 2024)": "Solitary plasmacytoma of bone",
        "Category": "Solitary plasmacytoma of bone",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "PCN",
        "L5": "Plasmacytoma bone",
        "L6": "Plasmacytoma bone"
    },
    {
        "ID": "076",
        "IHC Code": "IHC-006-076",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Plasma cell neoplasms (PCN)",
        "Subtype/entity(Interlymph 2024)": "Extraosseous plasmacytoma",
        "Category": "Extraosseous plasmacytoma",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "PCN",
        "L5": "Plasmacytoma extraosseous",
        "L6": "Plasmacytoma extraosseous"
    },
    {
        "ID": "077",
        "IHC Code": "IHC-006-077",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Plasma cell neoplasms (PCN)",
        "Subtype/entity(Interlymph 2024)": "Plasma cell myeloma (PCM)",
        "Category": "Plasma cell myeloma (PCM)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "PCN",
        "L5": "PCM",
        "L6": ""
    },
    {
        "ID": "078",
        "IHC Code": "IHC-006-078",
        "Table": "B-cell",
        "Main Category(2022 WHO)": "Plasma cell neoplasms and other diseases with paraproteins",
        "Family/class(2022 WHO)": "Plasma cell neoplasms (PCN)",
        "Subtype/entity(Interlymph 2024)": "Plasma cell neoplasms with associated paraneoplastic syndrome (-POEMS syndrome,-TEMPI syndrome, -AESOP syndrome)",
        "Category": "Plasma cell neoplasms with associated paraneoplastic syndrome (-POEMS syndrome,-TEMPI syndrome) (AESEOP not previously included)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Plasma cell neoplasms and other diseases with paraproteins",
        "L4": "PCN",
        "L5": "PCN-with syndrome",
        "L6": "PCN-POEMS, PCN-TEMPI, PCN-AESOP"
    },
    {
        "ID": "079",
        "IHC Code": "IHC-247-079",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "NA",
        "Family/class(2022 WHO)": "Tumour-like lesions with T-cell predominance",
        "Subtype/entity(Interlymph 2024)": "Kikuchi-Fujimoto disease",
        "Category": "NA",
        "L1": "NA",
        "L2": "NA",
        "L3": "NA",
        "L4": "NA",
        "L5": "NA",
        "L6": "NA"
    },
    {
        "ID": "080",
        "IHC Code": "IHC-247-080",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "NA",
        "Family/class(2022 WHO)": "Tumour-like lesions with T-cell predominance",
        "Subtype/entity(Interlymph 2024)": "Indolent T-lymphoblastic proliferation",
        "Category": "NA",
        "L1": "NA",
        "L2": "NA",
        "L3": "NA",
        "L4": "NA",
        "L5": "NA",
        "L6": "NA"
    },
    {
        "ID": "081",
        "IHC Code": "IHC-247-081",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "NA",
        "Family/class(2022 WHO)": "Tumour-like lesions with T-cell predominance",
        "Subtype/entity(Interlymph 2024)": "Autoimmune lymphoproliferative syndrome",
        "Category": "NA",
        "L1": "NA",
        "L2": "NA",
        "L3": "NA",
        "L4": "NA",
        "L5": "NA",
        "L6": "NA"
    },
    {
        "ID": "082",
        "IHC Code": "IHC-004-082",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Precursor T-cell neoplasms",
        "Family/class(2022 WHO)": "T-lymphoblastic leukemia/lymphoma",
        "Subtype/entity(Interlymph 2024)": "Precursor T acute lymphoblastic leukemia/lymphoma (T-ALL/LBL)",
        "Category": "Precursor T acute lymphoblastic leukemia/lymphoma (T-ALL/LBL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Precursor T-cell neoplasms",
        "L4": "T-lymphoblastic leukemia/lymphoma",
        "L5": "T-ALL/LBL, NOS",
        "L6": "T-ALL, LBL"
    },
    {
        "ID": "083",
        "IHC Code": "IHC-005-083",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Mature T-cell and NK-cell leukemias",
        "Subtype/entity(Interlymph 2024)": "T-cell prolymphocytic leukemia (T-PLL)",
        "Category": "T-cell prolymphocytic leukemia (T-PLL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Mature T-cell and NK-cell leukemias",
        "L5": "T-PLL",
        "L6": ""
    },
    {
        "ID": "084",
        "IHC Code": "IHC-005-084",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Mature T-cell and NK-cell leukemias",
        "Subtype/entity(Interlymph 2024)": "T-cell  large granular lymphocytic leukemia (T-LGLL)",
        "Category": "T-cell large granular lymphocytic leukemia (T-LGL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Mature T-cell and NK-cell leukemias",
        "L5": "T-LGLL ",
        "L6": ""
    },
    {
        "ID": "085",
        "IHC Code": "IHC-005-085",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Mature T-cell and NK-cell leukemias",
        "Subtype/entity(Interlymph 2024)": "Adult T-cell leukemia/lymphoma (ATLL)",
        "Category": "Adult T-cell leukemia/lymphoma (ATLL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Mature T-cell and NK-cell leukemias",
        "L5": "ATLL",
        "L6": ""
    },
    {
        "ID": "086",
        "IHC Code": "IHC-005-086",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Mature T-cell and NK-cell leukemias",
        "Subtype/entity(Interlymph 2024)": "Aggressive NK-cell leukemia (ANKL)",
        "Category": "Aggressive NK-cell leukemia (ANKL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Mature T-cell and NK-cell leukemias",
        "L5": "ANKL",
        "L6": ""
    },
    {
        "ID": "087",
        "IHC Code": "IHC-005-087",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Mature T-cell and NK-cell leukemias",
        "Subtype/entity(Interlymph 2024)": "Sezary syndrome (SS)",
        "Category": "Sezary syndrome (SS)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Mature T-cell and NK-cell leukemias",
        "L5": "SS",
        "L6": ""
    },
    {
        "ID": "088",
        "IHC Code": "IHC-005-088",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Mature T-cell and NK-cell leukemias",
        "Subtype/entity(Interlymph 2024)": "NK-Large granular lymphocytic leukemia  (NK-LGLL)",
        "Category": "Chronic lymphoproliferative disorders of NK cells (CLPD-NK)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Mature T-cell and NK-cell leukemias",
        "L5": "NK-LGLL",
        "L6": ""
    },
    {
        "ID": "089",
        "IHC Code": "IHC-005-089",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Primary cutaneous T-cell lymphomas (CTCL)",
        "Subtype/entity(Interlymph 2024)": "Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)",
        "Category": "Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "CTCL",
        "L5": "SPTCL",
        "L6": ""
    },
    {
        "ID": "090",
        "IHC Code": "IHC-005-090",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Primary cutaneous T-cell lymphomas (CTCL)",
        "Subtype/entity(Interlymph 2024)": "Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL)",
        "Category": "Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "CTCL",
        "L5": "PCGD-TCL",
        "L6": ""
    },
    {
        "ID": "091",
        "IHC Code": "IHC-005-091",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Primary cutaneous T-cell lymphomas (CTCL)",
        "Subtype/entity(Interlymph 2024)": "Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma (PCCD8-TCL)",
        "Category": "Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma (PCCD8-TCL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "CTCL",
        "L5": "PCCD8-TCL",
        "L6": ""
    },
    {
        "ID": "092",
        "IHC Code": "IHC-005-092",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Primary cutaneous T-cell lymphomas (CTCL)",
        "Subtype/entity(Interlymph 2024)": "Primary cutaneous T-cell lymphoma, NOS (PCTCL, NOS)",
        "Category": "Primary cutaneou T-cell lymphoma, NOS (PCTCL, NOS)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "CTCL",
        "L5": "PCTL,NOS",
        "L6": ""
    },
    {
        "ID": "093",
        "IHC Code": "IHC-025-093",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Primary cutaneous T-cell lymphomas (CTCL)",
        "Subtype/entity(Interlymph 2024)": "Primary cutaneous CD4 positive small/medium T-cell lymphoproliferative disorder (PCCD4-TCL)",
        "Category": "Primary cutaneous CD4 positive small/medium T-cell lymphoma (PCCD4-TCL)",
        "L1": "LN",
        "L2": "LPD",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "CTCL",
        "L5": "PCCD4-TCL",
        "L6": ""
    },
    {
        "ID": "094",
        "IHC Code": "IHC-005-094",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Primary cutaneous T-cell lymphomas (CTCL)",
        "Subtype/entity(Interlymph 2024)": "Mycosis fungoides (MF)",
        "Category": "Mycosis fungoides (MF)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "CTCL",
        "L5": "MF",
        "L6": ""
    },
    {
        "ID": "095",
        "IHC Code": "IHC-025-095",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Primary cutaneous T-cell lymphomas (CTCL)",
        "Subtype/entity(Interlymph 2024)": "Primary cutaneous CD30 positive T-cell lymphoproliferative disorders (CD30+PCLPD): Primary cutaneous anaplastic large cell lymphoma (C-ALCL)",
        "Category": "Primary cutaneous CD30 positive T-cell lymphoproliferative disorders (CD30+PCLPD): Primary cutaneous anaplastic large cell lymphoma (C-ALCL)",
        "L1": "LN",
        "L2": "LPD",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "CTCL",
        "L5": "CD30+PCLPD",
        "L6": "C-ALCL"
    },
    {
        "ID": "096",
        "IHC Code": "IHC-025-096",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Primary cutaneous T-cell lymphomas (CTCL)",
        "Subtype/entity(Interlymph 2024)": "Primary cutaneous CD30 positive lymphoproliferative disorders (CD30+PCLPD): Lymphomatid papulosis (LyP)",
        "Category": "Primary cutaneous CD30 positive lymphoproliferative disorders (CD30+PCLPD): Lymphomatid papulosis (LyP)",
        "L1": "LN",
        "L2": "LPD",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "CTCL",
        "L5": "CD30+PCLPD",
        "L6": "Lyp"
    },
    {
        "ID": "097",
        "IHC Code": "IHC-025-097",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Primary cutaneous T-cell lymphomas (CTCL)",
        "Subtype/entity(Interlymph 2024)": "Primary cutaneous acral CD8-positive lymphoproliferative disorder",
        "Category": "NA",
        "L1": "LN",
        "L2": "LPD",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "CTCL",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "098",
        "IHC Code": "IHC-025-098",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "Subtype/entity(Interlymph 2024)": "Indolent T-cell lymphoma of the gastrointestinal tract ",
        "Category": "Indolent T-cll lymphoproliferative disorder of the gastrointestinal tract",
        "L1": "LN",
        "L2": "LPD",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "L5": "Indolent T-cell lymphoma of the gastrointestinal tract  ",
        "L6": ""
    },
    {
        "ID": "099",
        "IHC Code": "IHC-025-099",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "Subtype/entity(Interlymph 2024)": "Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract (iNKLPD)",
        "Category": "Not previously included",
        "L1": "LN",
        "L2": "LPD",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "L5": "iNKLPD",
        "L6": ""
    },
    {
        "ID": "100",
        "IHC Code": "IHC-005-100",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "Subtype/entity(Interlymph 2024)": "Enteropathy-associated T-cell lymphoma (EATL)",
        "Category": "Enteropathy-associated T-cell lymphoma (EATL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "L5": "Enteropathy-associated T-cell lymphoma (EATL)",
        "L6": ""
    },
    {
        "ID": "101",
        "IHC Code": "IHC-005-101",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "Subtype/entity(Interlymph 2024)": "Intraepithelial (intestinal) T-cell lymphoma -in -situ (EATL-in situ)",
        "Category": "Intraepithelial (intestinal) T-cell lymphoma -in -situ (EATL-in situ)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "L5": "Intraepithelial (intestinal) T-cell lymphoma -in -situ (EATL-in situ)",
        "L6": ""
    },
    {
        "ID": "102",
        "IHC Code": "IHC-005-102",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "Subtype/entity(Interlymph 2024)": "Monomorphic epitheliotropic intestinal T-cell lymphoma",
        "Category": "Monomorphic epitheliotropic intestinal T-cell lymphoma",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "L5": "Monomorphic epitheliotropic intestinal T-cell lymphoma",
        "L6": ""
    },
    {
        "ID": "103",
        "IHC Code": "IHC-005-103",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "Subtype/entity(Interlymph 2024)": "Intestinal T-cell lymphoma, NOS",
        "Category": "Intestinal T-cell lymphoma, NOS",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas",
        "L5": "Intestinal T-cell lymphoma, NOS",
        "L6": ""
    },
    {
        "ID": "104",
        "IHC Code": "IHC-005-104",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Hepatosplenic T-cell lymphoma",
        "Subtype/entity(Interlymph 2024)": "Hepatosplenic T-cell lymphoma (HSTL)",
        "Category": "Hepatosplenic T-cell lymphoma (HSTL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "Hepatosplenic T-cell lymphoma",
        "L5": "HSTL",
        "L6": ""
    },
    {
        "ID": "105",
        "IHC Code": "IHC-005-105",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Anaplastic large cell lymphoma (ALCL)",
        "Subtype/entity(Interlymph 2024)": "ALK-positive anaplastic large cell lymphoma",
        "Category": "Anaplastic large cell lymphoma, ALK -positive ( ALCL, ALK+)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "ALCL",
        "L5": "ALK+ ALCL",
        "L6": ""
    },
    {
        "ID": "106",
        "IHC Code": "IHC-005-106",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Anaplastic large cell lymphoma (ALCL)",
        "Subtype/entity(Interlymph 2024)": "ALK-negative anaplastic large cell lymphoma",
        "Category": "Anaplastic large cell lymphoma, ALK-negative (ALCL, ALK-)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "ALCL",
        "L5": "ALK- ALCL",
        "L6": ""
    },
    {
        "ID": "107",
        "IHC Code": "IHC-005-107",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Anaplastic large cell lymphoma (ALCL)",
        "Subtype/entity(Interlymph 2024)": "Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)",
        "Category": "Breast implant-associated anaplastic large cell lymphoma",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "ALCL",
        "L5": "BIA-ALCL",
        "L6": ""
    },
    {
        "ID": "108",
        "IHC Code": "IHC-005-108",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Nodal T-follicular helper cell lymphoma (nTFHL)",
        "Subtype/entity(Interlymph 2024)": "Nodal TFH cell lymphoma, angioimmunoblastic-type",
        "Category": "Angioimmunoblastic T-cell lymphoma (AITL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "nTFHL",
        "L5": "nTFHL-AI",
        "L6": ""
    },
    {
        "ID": "109",
        "IHC Code": "IHC-005-109",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Nodal T-follicular helper cell lymphoma (nTFHL)",
        "Subtype/entity(Interlymph 2024)": "Nodal TFH cell lymphoma, follicular-type",
        "Category": "Follicular T-cell lymphoma",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "nTFHL",
        "L5": "nTFHL-F",
        "L6": ""
    },
    {
        "ID": "110",
        "IHC Code": "IHC-005-110",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Nodal T-follicular helper cell lymphoma (nTFHL)",
        "Subtype/entity(Interlymph 2024)": "Nodal TFH cell lymphoma, NOS",
        "Category": "Nodal peripheral T-cell lymphoma with TFH phenotype",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "nTFHL",
        "L5": "nTFHL-NOS",
        "L6": ""
    },
    {
        "ID": "111",
        "IHC Code": "IHC-005-111",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Other T-cell lymphomas",
        "Subtype/entity(Interlymph 2024)": "Peripheral T-cell lymphoma , NOS (PTCL,NOS)",
        "Category": "Peripheral T-cell lymphoma , NOS (PTCL,NOS)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "PTCL",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "112",
        "IHC Code": "IHC-005-112",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "Other T-cell lymphomas",
        "Subtype/entity(Interlymph 2024)": "NHL,NOS, T-cell",
        "Category": "NHL,NOS, T-cell",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "113",
        "IHC Code": "IHC-005-113",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "EBV-positive NK/T-cell lymphomas",
        "Subtype/entity(Interlymph 2024)": "EBV-positive nodal T- and NK-cell lymphoma",
        "Category": "Not previously included",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "EBV-positive NK/T-cell lymphomas",
        "L5": "EBV-positive nodal T- and NK-cell lymphoma",
        "L6": ""
    },
    {
        "ID": "114",
        "IHC Code": "IHC-005-114",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "EBV-positive NK/T-cell lymphomas",
        "Subtype/entity(Interlymph 2024)": "Extranodal NK/T-cell lymphoma (ENKTL) (JT: separate nasal and non-nasal?)",
        "Category": "Extranodal NK/T-cell lymphoma, nasal type (ENNKTL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "EBV-positive NK/T-cell lymphomas",
        "L5": "ENKTL",
        "L6": ""
    },
    {
        "ID": "115",
        "IHC Code": "IHC-005-115",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "EBV positive T- and NK-cell lymphoid proliferations and lymphomas of childhood",
        "Subtype/entity(Interlymph 2024)": "Severe mosquito bite allergy",
        "Category": "Severe mosquito bite allergy",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "EBV positive T- and NK-cell lymphoid proliferations and lymphomas of childhood",
        "L5": "Severe mosquito bite allergy",
        "L6": ""
    },
    {
        "ID": "116",
        "IHC Code": "IHC-005-116",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "EBV positive T- and NK-cell lymphoid proliferations and lymphomas of childhood",
        "Subtype/entity(Interlymph 2024)": "Systemic EBV-positive T-cell lymphoma of childhood",
        "Category": "Systemic EBV-positive T-cell lymphoma of childhood",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "EBV positive T- and NK-cell lymphoid proliferations and lymphomas of childhood",
        "L5": "Systemic EBV-positive T-cell lymphoma of childhood",
        "L6": ""
    },
    {
        "ID": "117",
        "IHC Code": "IHC-005-117",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "EBV positive T- and NK-cell lymphoid proliferations and lymphomas of childhood",
        "Subtype/entity(Interlymph 2024)": "Systemic chronic active EBV disease",
        "Category": "Systemic EBV positive T-cell lymphoproliferative disease of childhood (EBV+LPD-PED)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "EBV positive T- and NK-cell lymphoid proliferations and lymphomas of childhood",
        "L5": "Systemic chronic active EBV disease",
        "L6": ""
    },
    {
        "ID": "118",
        "IHC Code": "IHC-005-118",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Mature T-cell and NK-cell neoplasms",
        "Family/class(2022 WHO)": "EBV positive T- and NK-cell lymphoid proliferations and lymphomas of childhood",
        "Subtype/entity(Interlymph 2024)": "Hydroa vacciniforme lymphoproliferative disorder (HVL)",
        "Category": "Hydroa vacciniforme-like cutaneous EBV positive T-cell lymphoproliferative disease of childhood (HVL)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "EBV positive T- and NK-cell lymphoid proliferations and lymphomas of childhood",
        "L5": "Hydroa vacciniforme lymphoproliferative disorder (HVL)",
        "L6": ""
    },
    {
        "ID": "119",
        "IHC Code": "IHC-007-119",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "NHL, NOS, unknown lineage (?)",
        "Family/class(2022 WHO)": "NA",
        "Subtype/entity(Interlymph 2024)": "Precursor (acute) lymphoblastic leukemia/lymphoma, unknown lineage (ALL/LBL (U))",
        "Category": "Precursor (acute) lymphoblastic leukemia/lymphoma, unknown lineage (ALL/LBL (U))",
        "L1": "LN",
        "L2": "NHL",
        "L3": "",
        "L4": "",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "120",
        "IHC Code": "IHC-007-120",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "NHL, NOS, unknown lineage (?)",
        "Family/class(2022 WHO)": "NA",
        "Subtype/entity(Interlymph 2024)": "NHL,NOS,unknown lineage",
        "Category": "NHL,NOS,unknown lineage",
        "L1": "LN",
        "L2": "NHL",
        "L3": "",
        "L4": "",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "121",
        "IHC Code": "IHC-007-121",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "NHL, NOS, unknown lineage (?)",
        "Family/class(2022 WHO)": "NA",
        "Subtype/entity(Interlymph 2024)": "Lymphoid neoplasm, NOS, unknown lineage",
        "Category": "Lymphoid neoplasm, NOS, unknown lineage",
        "L1": "LN",
        "L2": "NHL",
        "L3": "",
        "L4": "",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "122",
        "IHC Code": "IHC-037-122",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Multiple coexisting lymphoma subtypes",
        "Family/class(2022 WHO)": "NA",
        "Subtype/entity(Interlymph 2024)": "Composite Hodgkin/non-Hodgkin lymphoma (specify)",
        "Category": "Composite Hodgkin/non-Hodgkin lymphoma (specify)",
        "L1": "LN",
        "L2": "HL/NHL",
        "L3": "",
        "L4": "",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "123",
        "IHC Code": "IHC-007-123",
        "Table": "T-cell and NK-cell",
        "Main Category(2022 WHO)": "Multiple coexisting lymphoma subtypes",
        "Family/class(2022 WHO)": "NA",
        "Subtype/entity(Interlymph 2024)": "Non-Hodgkin lymphoma of more than one histological type (specify)",
        "Category": "Non-Hodgkin lymphoma of more than one histological type (specify)",
        "L1": "LN",
        "L2": "NHL",
        "L3": "",
        "L4": "",
        "L5": "",
        "L6": ""
    },
    {
        "ID": "124",
        "IHC Code": "IHC-122-124",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Post-transplant lymphoproliferative disorders (PTLD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PTLD early lesions: Plasmacytic hyperplasia (PTLD-PH)",
        "L1": "LN-ID",
        "L2": "LPD",
        "L3": "Mature B-LPD",
        "L4": "PTLD",
        "L5": "PTLD-PH",
        "L6": ""
    },
    {
        "ID": "125",
        "IHC Code": "IHC-122-125",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Post-transplant lymphoproliferative disorders (PTLD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PTLD early lesions: Infectious mononucleosis-like PTLD (PTLD-IM-like)",
        "L1": "LN-ID",
        "L2": "LPD",
        "L3": "Mature B-LPD",
        "L4": "PTLD",
        "L5": "PTLD-IM-like",
        "L6": ""
    },
    {
        "ID": "126",
        "IHC Code": "IHC-122-126",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Post-transplant lymphoproliferative disorders (PTLD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PTLD polymorphic (PTLD-P)",
        "L1": "LN-ID",
        "L2": "LPD",
        "L3": "Mature B-LPD",
        "L4": "PTLD",
        "L5": "PTLD-PH",
        "L6": ""
    },
    {
        "ID": "127",
        "IHC Code": "IHC-103-127",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Post-transplant lymphoproliferative disorders (PTLD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PTLD monomorphic B-cell (specify) (PTLD-M-B-cell)",
        "L1": "LN-ID",
        "L2": "NHL",
        "L3": "Mature B-NHL",
        "L4": "PTLD",
        "L5": "PTLD-M-B-cell",
        "L6": ""
    },
    {
        "ID": "128",
        "IHC Code": "IHC-105-128",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Post-transplant lymphoproliferative disorders (PTLD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PTLD monomorphic T- or NK -cell (specify) (PTLD-M-T-or NK- cell)",
        "L1": "LN-ID",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "PTLD",
        "L5": "PTLD-M-T-cell",
        "L6": ""
    },
    {
        "ID": "129",
        "IHC Code": "IHC-117-129",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Post-transplant lymphoproliferative disorders (PTLD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "Classical Hodgkin lymphoma type PTLD (PTLD-CHL)",
        "L1": "LN-ID",
        "L2": "HL",
        "L3": "?",
        "L4": "PTLD",
        "L5": "PTLD-CHL",
        "L6": ""
    },
    {
        "ID": "130",
        "IHC Code": "IHC-122-130",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Lymphoproliferative diseases associated with primary immune disorders (PID-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PID-early and PTLD-like polymorphous lymphoid proliferations (PID-LPD-P)",
        "L1": "LN-ID",
        "L2": "LPD",
        "L3": "Mature B-LPD",
        "L4": "PID-LPD",
        "L5": "PID-LPD-P",
        "L6": ""
    },
    {
        "ID": "131",
        "IHC Code": "IHC-103-131",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Lymphoproliferative diseases associated with primary immune disorders (PID-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PID-B-cell NHL (Specify) (PID-LPD-B-cell)",
        "L1": "LN-ID",
        "L2": "NHL",
        "L3": "Mature B-NHL",
        "L4": "PID-LPD",
        "L5": "PID-LPD-B-cell",
        "L6": ""
    },
    {
        "ID": "132",
        "IHC Code": "IHC-105-132",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Lymphoproliferative diseases associated with primary immune disorders (PID-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PID-mature T- or NK-cell NHL (specify) (PID-LPD-T or NK Cell)",
        "L1": "LN-ID",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "PID-LPD",
        "L5": "PID-LPD-T or NK cell",
        "L6": ""
    },
    {
        "ID": "133",
        "IHC Code": "IHC-104-133",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Lymphoproliferative diseases associated with primary immune disorders (PID-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PID-T lymphoblastic leukemia/lymphoma (PID-T-ALL/LBL)",
        "L1": "LN-ID",
        "L2": "NHL",
        "L3": "Precursor T-cell neoplasms",
        "L4": "PID-LPD",
        "L5": "PID-T-ALL/LBL",
        "L6": ""
    },
    {
        "ID": "134",
        "IHC Code": "IHC-117-134",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Lymphoproliferative diseases associated with primary immune disorders (PID-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "PID-LPD classical Hodgkin lymphoma (PID-CHL)",
        "L1": "LN-ID",
        "L2": "HL",
        "L3": "?",
        "L4": "PID-LPD",
        "L5": "PID-CHL",
        "L6": ""
    },
    {
        "ID": "135",
        "IHC Code": "IHC-122-135",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Lymphoproliferative disorders associated with HIV infection (HIV-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "HIV-PTLD-like polymorphous lymphoid proliferations (HIV-LPD-P)",
        "L1": "LN-ID",
        "L2": "LPD",
        "L3": "Mature B-LPD",
        "L4": "HIV-LPD",
        "L5": "HIV-LPD-P",
        "L6": ""
    },
    {
        "ID": "136",
        "IHC Code": "IHC-103-136",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Lymphoproliferative disorders associated with HIV infection (HIV-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "HIV-B-cell NHL (specify) (HIV-LPD-B-cell)",
        "L1": "LN-ID",
        "L2": "NHL",
        "L3": "Mature B-NHL",
        "L4": "HIV-LPD",
        "L5": "HIV-LPD-B-cell",
        "L6": ""
    },
    {
        "ID": "137",
        "IHC Code": "IHC-105-137",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Lymphoproliferative disorders associated with HIV infection (HIV-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "HIV-T or NK-cell NHL (specify) (HIV-LPD-T or NK-cell)",
        "L1": "LN-ID",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "HIV-LPD",
        "L5": "HIV-LPD-T or NK cell",
        "L6": ""
    },
    {
        "ID": "138",
        "IHC Code": "IHC-117-138",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Lymphoproliferative disorders associated with HIV infection (HIV-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "HIV-classical Hodgkin lymphoma (HIV-CHL)",
        "L1": "LN-ID",
        "L2": "HL",
        "L3": "?",
        "L4": "HIV-LPD",
        "L5": "HIV-CHL",
        "L6": ""
    },
    {
        "ID": "139",
        "IHC Code": "IHC-122-139",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Liatrogenic lymphoproliferative disorders associated with non-transplant immunosuppressive drug therapy (IAT-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "IAT-PTLD-like polymorphous lymphoid proliferations (IAT-LPD-P)",
        "L1": "LN-ID",
        "L2": "LPD",
        "L3": "Mature B-LPD",
        "L4": "IAT-LPD",
        "L5": "IAT-LPD-P",
        "L6": ""
    },
    {
        "ID": "140",
        "IHC Code": "IHC-103-140",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Liatrogenic lymphoproliferative disorders associated with non-transplant immunosuppressive drug therapy (IAT-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "IAT-B-cell NHL (specify) (IAT-LPD-B-cell)",
        "L1": "LN-ID",
        "L2": "NHL",
        "L3": "Mature B-NHL",
        "L4": "IAT-LPD",
        "L5": "IAT-LPD-B-cell",
        "L6": ""
    },
    {
        "ID": "141",
        "IHC Code": "IHC-105-141",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Liatrogenic lymphoproliferative disorders associated with non-transplant immunosuppressive drug therapy (IAT-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "IAT-T or NK- cell NHL (specify) (IAT-LPD-T or NK-cell)",
        "L1": "LN-ID",
        "L2": "NHL",
        "L3": "Mature T-cell and NK-cell neoplasms",
        "L4": "IAT-LPD",
        "L5": "IAT-LPD-T or NK cell",
        "L6": ""
    },
    {
        "ID": "142",
        "IHC Code": "IHC-117-142",
        "Table": "Immunodeficiency-associated LPD",
        "Main Category(2022 WHO)": "Liatrogenic lymphoproliferative disorders associated with non-transplant immunosuppressive drug therapy (IAT-LPD)",
        "Family/class(2022 WHO)": "?",
        "Subtype/entity(Interlymph 2024)": "?",
        "Category": "IAT-classical Hodgkin lymphoma (IAT-CHL)",
        "L1": "LN-ID",
        "L2": "HL",
        "L3": "?",
        "L4": "IAT-LPD",
        "L5": "IAT-CHL",
        "L6": ""
    }
]